NUT midline carcinoma: Morphoproteomic characterization with genomic and therapeutic correlates

Annals of Clinical and Laboratory Science

Volumn 45, Issue 6, 2015, Pages 692-701

  Sun, Hongxia ^a   McGuire, Mary F ^a   Zhang, Songlin ^a   Brown, Robert E ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Biomedical analytics; C Myc; EZH2; Morphoproteomic; MTORC2 pathway; NUT midline carcinoma; Sirt1

Indexed keywords

ANTIBODY; CURCUMIN; HISTONE METHYLTRANSFERASE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MELATONIN; METFORMIN; SIRTUIN 1; SOMATOMEDIN C RECEPTOR; SULFORAPHANE; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR SOX2; VORINOSTAT; EZH2 PROTEIN, HUMAN; ISOTHIOCYANIC ACID DERIVATIVE; MTOR PROTEIN, HUMAN; NUCLEAR PROTEIN; NUT PROTEIN, HUMAN; ONCOPROTEIN; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN KINASE B; SIRT1 PROTEIN, HUMAN; SULFORAFAN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CANCER CELL; CELL DIFFERENTIATION; GENE; GENOMICS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; NUCLEAR PROTEIN IN TESTIS GENE; NUT MIDLINE CARCINOMA; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEOMICS; TESTIS CARCINOMA; ADOLESCENT; ADULT; CARCINOMA; CASE REPORT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; MEDIASTINAL NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES;

ADOLESCENT; ADULT; CARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; ISOTHIOCYANATES; MALE; MEDIASTINAL NEOPLASMS; METFORMIN; MOLECULAR TARGETED THERAPY; NUCLEAR PROTEINS; ONCOGENE PROTEINS; POLYCOMB REPRESSIVE COMPLEX 2; PROTO-ONCOGENE PROTEINS C-AKT; SIRTUIN 1; TOR SERINE-THREONINE KINASES;

EID: 84950249972     PISSN: 00917370     EISSN: 15508080     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Kubonishi I, Takehara N, Iwata J, Sonobe H, Ohtsuki Y, Abe T, Miyoshi I. Novel t(15;19)(q15;p13) chromosome abnormality in a thymic carcinoma. Cancer Res 1991;51:3327-3328.
2. French CA, Miyoshi I, Kubonishi I, Grier HE, Perez-Atayde AR, Fletcher JA. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res 2003;63:304-307.
3. French CA, Kutok JL, Faquin WC, Toretsky JA, Antonescu CR, Griffin CA, Nose V, Vargas SO, Moschovi M, Tzortzatou-Stathopoulou F, Miyoshi I, Perez-Atayde AR, Aster JC, Fletcher JA. Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol 2004;22:4135-4139.
4. French CA. NUT midline carcinoma. Cancer Genet Cytogenet 2010;203:16-20.
5. Stelow EB. A review of NUT midline carcinoma. Head Neck Pathol 2011;5:31-35.
6. Evans AG, French CA, Cameron MJ, Fletcher CD, Jackman DM, Lathan CS, Sholl LM. Pathologic characteristics of NUT midline carcinoma arising in the mediastinum. Am J Surg Pathol 2012;36:1222-1227.
7. French CA. The importance of diagnosing NUT midline carcinoma. Head Neck Pathol 2013;7:11-16.
8. Bauer DE, Mitchell CM, StraitKM, Lathan CS, Stelow EB, Lüer SC, Muhammed S, Evans AG, Sholl LM, Rosai J, Giraldi E, Oakley RP, Rodriguez-Galindo C, London WB, Sallan SE, Bradner JE, French CA. Clinicopathologic features and longterm outcomes of NUT midline carcinoma. Clin Cancer Res. 2012;18:5773-5779.
9. French CA, Ramirez CL, Kolmakova J, Hickman TT, Cameron MJ, Thyne ME, Kutok JL, Toretsky JA, Tadavarthy AK, Kees UR, Fletcher JA, Aster JC. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene 2008;27:2237-2242.
10. French CA. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol 2012;7:247-265.
11. Morinière J, Rousseaux S, Steuerwald U, Soler-López M, Curtet S, Vitte AL, Govin J, Gaucher J, Sadoul K, Hart DJ, Krijgsveld J, Khochbin S, Müller CW, Petosa C. Cooperative binding of two acetylation marks on a histone tail by a single bromodomain. Nature 2009;461:664-668.
12. Dey A, Chitsaz F, Abbasi A, Misteli T, Ozato K. The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc Natl Acad Sci U S A 2003;100:8758-8763.
13. Reynoird N, Schwartz BE, Delvecchio M, Sadoul K, Meyers D, Mukherjee C, Caron C, Kimura H, Rousseaux S, Cole PA, Panne D, French CA, Khochbin S. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J. 2010;29:2943-2952.
14. Schwartz BE, HoferMD, Lemieux ME, Bauer DE, Cameron MJ, West NH, Agoston ES, Reynoird N, Khochbin S, Ince TA, Christie A, Janeway KA, Vargas SO, Perez-Atayde AR, Aster JC, Sallan SE, Kung AL, Bradner JE, French CA. Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res 2011;71:2686-2696.
15. Grayson AR, Walsh EM, Cameron MJ, Godec J, Ashworth T, Ambrose JM, Aserlind AB, Wang H, Evan GI, Kluk MJ, Bradner JE, Aster JC, French CA. MYC, a downstream target of BRDNUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma. Oncogene 2014;33:1736-1742.
16. Brown RE. Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients. Expert Rev Proteomics 2005;2:337-348.
17. Brown RE. Morphogenomics and morphoproteomics: a role for anatomic pathology in personalized medicine. Arch Pathol Lab Med 2009;133:568-579.
18. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-484.
19. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007;12:487-502.
20. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22.
21. Nishitani S, Horie M, Ishizaki S, Yano H. Branched chain amino acid suppresses hepatocellular cancer stem cells through the activation of mammalian target of rapamycin. PLoS One 2013;8:e82346.
22. Francipane MG, Lagasse E. Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1. Oncotarget 2013;4:1948-1962.
23. Lee KS, Wu Z, Song Y, Mitra SS, Feroze AH, Cheshier SH, Lu B. Roles of PINK1, mTORC2, and mitochondria in preserving brain tumor-forming stem cells in a noncanonical Notch signaling pathway. Genes Dev 2013;27:2642-2647.
24. Rosner M, Siegel N, Valli A, Fuchs C, Hengstschläger M. mTOR phosphorylated at S2448 binds to raptor and rictor. Amino Acids. 2010;38:223-228.
25. Rosner M, Hengstschläger M. Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. Hum Mol Genet. 2008;17:2934-2948.
26. Hresko RC, Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem. 2005;280:40406-40416.
27. Zakikhani M, Blouin MJ, Piura E, Pollak MN. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat. 2010;123:271-279.
28. Bosch-Presegué L, Vaquero A. The dual role of sirtuins in cancer. Genes Cancer 2011;2:648-662.
29. Bruzzone S, Parenti MD, Grozio A, Ballestrero A, Bauer I, Del Rio A, Nencioni A. Rejuvenating sirtuins: the rise of a new family of cancer drug targets. Curr Pharm Des 2013;19:614-623.
30. Song NY, Surh YJ. Janus-faced role of SIRT1 in tumorigenesis. Ann N Y Acad Sci 2012;1271:10-19.
31. Calvanese V, Lara E, Suárez-Alvarez B, Abu Dawud R, Vázquez-Chantada M, Martínez-Chantar ML, Embade N, López-Nieva P, Horrillo A, Hmadcha A, Soria B, Piazzolla D, Herranz D, Serrano M, Mato JM, Andrews PW, López-Larrea C, Esteller M, Fraga MF. Sirtuin 1 regulation of developmental genes during differentiation of stem cells. Proc Natl Acad Sci U S A 2010;107:13736-13741.
32. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, Chevalier B, Johnstone SE, Cole MF, Isono K, Koseki H, Fuchikami T, Abe K, Murray HL, Zucker JP, Yuan B, Bell GW, Herbolsheimer E, Hannett NM, Sun K, Odom DT, Otte AP, Volkert TL, Bartel DP, Melton DA, Gifford DK, Jaenisch R, Young RA. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 2006;125:301-313.
33. Richter GH, Plehm S, Fasan A, Rössler S, Unland R, Bennani-Baiti IM, Hotfilder M, Löwel D, von Luettichau I, Mossbrugger I, Quintanilla-Martinez L, Kovar H, Staege MS, Müller-Tidow C, Burdach S. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci U S A 2009;106:5324-5329.
34. Chang CJ, Hung MC. The role of EZH2 in tumour progression. Br J Cancer 2012;106:243-247.
35. Mao B, Zhao G, Lv X, Chen HZ, Xue Z, Yang B, Liu DP, Liang CC. Sirt1 deacetylates c-Myc and promotes c-Myc/Max association. Int J Biochem Cell Biol 2011;43:1573-1581.
36. Menssen A, Hydbring P, Kapelle K, Vervoorts J, Diebold J, Lüscher B, Larsson LG, Hermeking H. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad Sci U S A 2012;109:E187-E196.
37. Bouras T, Fu M, Sauve AA, Wang F, Quong AA, Perkins ND, Hay RT, Gu W, Pestell RG. SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain.J Biol Chem 2005;280:10264-10276.
38. Sankar N, Baluchamy S, Kadeppagari RK, Singhal G, Weitzman S, Thimmapaya B. P300 provides a corepressor function by cooperating with YY1 and HDAC3 to repress c-Myc. Oncogene 2008;27:5717-5728.
39. Zhao X, Lwin T, Zhang X, Huang A, Wang J, Marquez VE, Chen-Kiang S, Dalton WS, Sotomayor E, Tao J. Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. Leukemia 2013;27:2341-2350.
40. Cho HM, Jeon HS, Lee SY, Jeong KJ, Park SY, Lee HY, Lee JU, Kim JH, Kwon SJ, Choi E, Na MJ, Kang J, Son JW. MicroRNA-101 inhibits lung cancer invasion through the regulation of enhancer of zeste homolog 2. Exp Ther Med 2011;2:963-967.
41. Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, Chen YC, Peng Y, Yao KT, Kung HF, Li XP. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res. 2011;71:225-233.
42. Wang L, Zhang X, Jia LT, Hu SJ, Zhao J, Yang JD, Wen WH, Wang Z, Wang T, Zhao J, Wang RA, Meng YL, Nie YZ, Dou KF, Chen SY, Yao LB, Fan DM, Zhang R, Yang AG. c-Mycmediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology 2014;59:1850-1863.
43. Konno Y, Dong P, Xiong Y, Suzuki F, Lu J, Cai M, Watari H, Mitamura T, Hosaka M, Hanley SJ, Kudo M, Sakuragi N. MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells. Oncotarget 2014;5:6049-6062.
44. Eades G, Yao Y, Yang M, Zhang Y, Chumsri S, Zhou Q. miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J Biol Chem. 2011;286(29):25992-26002.
45. Zhu Z, Jiang W, McGinley JN, Thompson HJ. Defining the role of histone deacetylases in the inhibition of mammary carcinogenesis by dietary energy restriction (DER): effects of suberoylanilide hydroxamic acid (SAHA) and DER in a rat model. Cancer Prev Res (Phila). 2013;6:290-298.
46. Xu Y, Voelter-Mahlknecht S, Mahlknecht U. The histone deacetylase inhibitor suberoylanilide hydroxamic acid downregulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines. Int J Mol Med. 2005;15:169-172.
47. Silva G, Cardoso BA, Belo H, Almeida AM. Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms. PLoS One. 2013;8:e53766.
48. Maher OM, Christensen AM, Yedururi S, Bell D, Tarek N. Histone deacetylase inhibitor for NUT midline carcinoma. Pediatr Blood Cancer. 2015;62:715-717.
49. Orzan F, Pellegatta S, Poliani PL, Pisati F, Caldera V, Menghi F, Kapetis D, Marras C, Schiffer D, Finocchiaro G. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. Neuropathol Appl Neurobiol. 2011;37:381-394.
50. Sarfstein R, Bruchim I, Fishman A, Werner H. The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway. PLoS One 2011;6:e24468.
51. Kurundkar D, Srivastava RK, Chaudhary SC, Ballestas ME, Kopelovich L, Elmets CA, Athar M. Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model. Toxicol Appl Pharmacol 2013;266:233-244.